[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cutaneous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cutaneous":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100634382","epidemiology-and-management-of-cutaneous-t-cell-lymphoma-at-hospital-mxico-costa-rica-100634382",false,"NCT07538960","Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.","Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.\n* Patients aged 18 years or older, of both sexes.\n* Patients with at least one dermatological evaluation recorded during the study period.\n* Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and\u002For systemic treatments.\n\nExclusion Criteria:\n\n* Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.\n* Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.\n* Duplicate or inconsistent records that hinder the correct identification and classification of the patient.\n* Patients attended outside the established study period.\n* Patients outside the age range.\n* Patients who do not belong to the Dermatology Service of Hospital México.","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","OBSERVATIONAL","Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.",[24,25,26],"Lymph Node Cancer","Cutaneous","T-cell Lymphoma",[28,29,30,31],"Linfoma","Cutaneous Lymphoma","T-Cell Lymphoma","Therapy","NOT_YET_RECRUITING","2026-04-13",{"date":35,"type":36},"2026-04-20","ACTUAL",{"date":38,"type":20},"2026-05",{"date":40,"type":20},"2027-05",{"name":42,"class":43},"Caja Costarricense de Seguro Social","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100618864","stereotactic-post-operative-radiotherapy-for-intraparotid-metastatic-cutaneous-squamous-cell-carcinoma-100618864","NCT07337161","Stereotactic Post-operative Radiotherapy for Intraparotid Metastatic Cutaneous Squamous Cell Carcinoma","SPRINT","Inclusion criteria\n\n* Age ≥ 18 years\n* Patient able to provide informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Patient is a candidate for curative intent treatment\n* Patient is able to comprehend English adequately to complete patient reported outcome questionnaires\n* Biopsy-confirmed cutaneous SCC\n* Definitive resection of a primary cutaneous tumor within the head and neck\n* Tumor stage T1-T4 (AJCC 8th edition); or tumor stage unknown (T0\u002FTx) with a positive intraparotid, peri-parotid or cervical node that is assumed to be from a head and neck cutaneous SCC by the treating oncologist\n* Nodal stage N1-N3 (AJCC 8th edition)\n* At least 1 indication for adjuvant radiation, including:\n\n  * T3 or T4 tumor stage\n  * Lymphovascular invasion (LVI)\n  * Perineural invasion (PNI)\n  * Positive or close (≤ 3 mm) margin\n  * ≥ 1 positive intraparotid, peri-parotid or cervical lymph node\n  * Multiple local recurrences or multi-focal disease\n* Neoadjuvant or adjuvant immunotherapy is allowed\n\nExclusion criteria\n\n* Definite metastatic disease at diagnosis\n* Pregnant or breastfeeding women\n* Significant health conditions or contraindications to receiving surgery and radiation\n* History of previous head and neck cancer within 5 years, except for localized skin cancers (i.e. no nodal or distant spread)\n* Prior head and neck radiation involving the ipsilateral parotid or neck. However, prior radiation to the index skin cancer that has led to the parotid nodal disease being treated on this trial is allowed, as long as there is no overlap, or inconsequential overlap, in the judgement of the treating oncologist.\n* Indications for contralateral neck radiation (i.e. contralateral or bilateral lymph nodes)\n* Previous invasive malignancy within 5 years, unless controlled with no evidence of disease",{"count":53,"type":20},90,"INTERVENTIONAL",[56],"NA","The purpose of this study is to compare the effectiveness and side effects of stereotactic radiotherapy (5 sessions) against conventional (standard) radiotherapy (20-30 sessions) for the treatment of skin cancer involving the head and neck after surgical resection.\n\nStereotactic radiotherapy works in the same way that conventional (standard) radiotherapy does to kill cancer cells by damaging their genetic material and stopping the cancer cells from making copies of themselves.\n\nThis study will help the study doctors find out if this different approach is the same, better, or worse than the standard of care for your cancer.",[25,59],"Head and Neck Cancer Squamous Cell Carcinoma",[61,62,63,64,65],"skin","head and neck","radiation","SBRT","SABR","RECRUITING","2026-01-06",{"date":69,"type":36},"2026-01-13",{"date":71,"type":36},"2025-10-21",{"date":73,"type":20},"2035-09-01",{"name":75,"class":76},"David Palma","OTHER"]